Research ArticleClinical Studies

Efficacy of Nivolumab and Pembrolizumab in Platinum-sensitive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

GAI YAMASHITA, ISAKU OKAMOTO, TATSUYA ITO, KUNIHIKO TOKASHIKI, TAKURO OKADA and KIYOAKI TSUKAHARA
Anticancer Research August 2023, 43 (8) 3679-3683; DOI: https://doi.org/10.21873/anticanres.16550

Article Information

vol. 43 no. 8 3679-3683
DOI 
https://doi.org/10.21873/anticanres.16550
PMID 
37500154
Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received May 17, 2023
  • Revision received June 7, 2023
  • Accepted June 8, 2023
  • Published online July 26, 2023.
Copyright & Usage 
Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Author Information

  1. GAI YAMASHITA,
  2. ISAKU OKAMOTO⇑,
  3. TATSUYA ITO,
  4. KUNIHIKO TOKASHIKI,
  5. TAKURO OKADA and
  6. KIYOAKI TSUKAHARA
  1. Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan
  1. Correspondence to: Isaku Okamoto, MD, Ph.D., Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan. Tel: +81 333426111, Fax: +81 333469275, e-mail: isaku{at}tokyo-med.ac.jp
View Full Text

Statistics from Altmetric.com

Cited By...

Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Efficacy of Nivolumab and Pembrolizumab in Platinum-sensitive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
GAI YAMASHITA, ISAKU OKAMOTO, TATSUYA ITO, KUNIHIKO TOKASHIKI, TAKURO OKADA, KIYOAKI TSUKAHARA
Anticancer Research Aug 2023, 43 (8) 3679-3683; DOI: 10.21873/anticanres.16550
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords